Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading due to clinical trial updates, regulatory advancements, and investor anticipation for upcoming data releases [1] Company Updates - Alumis Inc. (ALMS) saw a surge of 17.33% to $9.75, gaining $1.44 after announcing that topline data from its Phase 3 ONWARD clinical program for envudeucitinib in moderate-to-severe plaque psoriasis will be reported on January 6, 2026, along with a conference call to discuss the results [2] - Genelux Corp. (GNLX) climbed 10.92% to $3.86, up $0.38, following interim results from ongoing trials evaluating Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [3] - Bright Minds Biosciences Inc. (DRUG) rose 8.42% to $86.75, gaining $6.74, and announced a conference call on January 6, 2026, to report topline results from its Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures [4] - Context Therapeutics Inc. (CNTX) shares increased by 8.36% to $1.68, adding $0.13, despite no specific news released [4] - BioAtla, Inc. (BCAB) gained 3.95% to $0.44, up $0.017, after announcing a special purpose vehicle transaction to advance ozuriftamab vedotin in a Phase 3 study for oropharyngeal squamous cell carcinoma, receiving $5 million in initial funding [5] - Femasys Inc. (FEMY) added 7.09% to $0.6223, up $0.04, with no new updates reported [5] - Acumen Pharmaceuticals, Inc. (ABOS) jumped 11.62% to $2.21, gaining $0.23, also without new corporate updates [6] - Alpha Tau Medical Ltd. (DRTS) rose 5.36% to $5.50, up $0.28, after submitting the first module of its pre-market approval application to the FDA for Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma [7]

Core Insights - GH Research PLC shares increased by 18.1% to $15.64 in pre-market trading following the announcement of an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression [1] Gainers - MKDWELL Tech Inc surged 61.2% to $0.27 after agreeing to repurchase 34,580,000 ordinary shares at $0.203/share, totaling $7 million [4] - Regencell Bioscience Holdings Ltd gained 52% to $31.21 after a previous decline of 2% [4] - Datavault AI Inc rose 26.7% to $1.28 after a 55% increase on the previous trading day [4] - Sidus Space Inc increased by 21.9% to $5.28 following a 38% rise on Friday [4] - Kazia Therapeutics Ltd rose 21.7% to $6.08 after a 27% decline on Friday [4] - Context Therapeutics Inc gained 18.7% to $1.84 after a 5% increase on Friday [4] - Hyperscale Data Inc rose 18.6% to $0.32 after a 49% jump on Friday [4] - PBF Energy Inc increased by 16.7% to $33.30 after providing updates on Martinez refinery operations and 2026 annual guidance [4] - Bioatla Inc rose 16.1% to $0.62 after a dip of more than 5% on Friday [4] Losers - Salarius Pharmaceuticals Inc fell 21.8% to $0.51 in pre-market trading [4] - Gain Therapeutics Inc decreased by 21.4% to $2.50 [4] - SBC Medical Group Holdings Inc declined 18.9% to $3.51 [4] - Polyrizon Ltd dropped 11.7% to $11.24 after a 50% gain on Friday [4] - ChowChow Cloud International HLDG Ltd dipped 10.3% to $0.71 after a 30% increase on Friday [4] - Lavoro Ltd shares fell 9.1% to $1.00 after a 144% jump on Friday [4] - Vicarious Surgical Inc decreased by 7.9% to $2.32 after a 16% gain on Friday [4] - Theravance Biopharma Inc dipped 6% to $17.07 after a 3% decline on Friday [4] - Comcast Corp tumbled 4.6% to $28.18 [4] - Equinor ASA fell 3.6% to $23.66 after a 4% increase on Friday [4]

Core Insights - Biotechnology stocks experienced significant movements in after-hours trading, with several companies reporting strong gains driven by positive trial results and strategic announcements [1] Company Performances - Exicure, Inc. (XCUR) saw a substantial increase of 72.61% to $9.20 after announcing positive Phase 2 trial results for burixafor, achieving a primary endpoint success rate of approximately 90% in multiple myeloma patients [2] - Artiva Biotherapeutics, Inc. (ARTV) rose 10.39% to $3.40 despite a regular session decline, with no new updates reported [3] - iBio, Inc. (IBIO) advanced 8.38% to $1.81, following a significant 39.17% increase during regular trading [3] - Cartesian Therapeutics, Inc. (RNAC) increased by 6.55% to $7.16, recovering from a prior decline [4] - Metagenomi, Inc. (MGX) gained 7.18% to $1.94, with plans to present preclinical data at an upcoming conference [5] - BioAtla, Inc. (BCAB) rose 4.81% to $0.85, despite no new updates [6] - ProMIS Neurosciences, Inc. (PMN) climbed 3.02% to $7.85, following a publication related to Alzheimer's disease biomarkers [7] - DiaMedica Therapeutics Inc. (DMAC) increased by 4.77% to $9.18, with no new announcements [8] - Wave Life Sciences Ltd. (WVE) shares surged 4.97% to $19.44 after a significant 147.26% increase during regular trading, linked to a $250 million public offering [9] - Assembly Biosciences, Inc. (ASMB) gained 5.96% to $37.49, reporting positive interim results from Phase 1b studies of HSV inhibitors [10]

Core Insights - Several small-cap biotech and healthcare stocks experienced significant gains in after-hours trading on November 28, 2025, despite a lack of new news [1] Company Summaries - **BioAtla Inc. (BCAB)**: Shares surged 13.94% to $1.03 after closing at $0.9040, up 6.27%. The increase may be linked to financing agreements announced on November 21, including a $7.5 million advance and a Standby Equity Purchase Agreement allowing for the sale of up to $15 million in common stock at a 3% discount [2] - **Metagenomi Inc. (MGX)**: Stock rose 5.71% to $1.85 after a 3.55% gain to $1.75 during regular trading. The movement appears driven by investor sentiment or technical factors, with no new corporate updates [3] - **PAVmed Inc. (PAVM)**: Advanced 5.72% to $0.3900, recovering from a slight decline earlier in the day. The company reported a GAAP net loss of $6.3 million, or $(0.29) per share, with revenue dropping sharply to $5,000 from $996,000 year-over-year [4] - **Precision BioSciences, Inc. (DTIL)**: Gained 2.94% to $5.60, building on a 6.46% rise to $5.44. The company is set to present Phase 1 data from its ELIMINATE-B trial at the Hep-DART 2025 meeting, which may be boosting investor optimism [5] - **Reviva Pharmaceuticals Holdings, Inc. (RVPH)**: Edged up 2.04% to $0.57 after a 7.66% gain to $0.5625. The company narrowed its quarterly net loss to $4.0 million, or $0.06 per share, compared to $8.4 million, or $0.25 per share, in the prior year [6] - **Sonnet BioTherapeutics Holdings, Inc. (SONN)**: Rose 5.11% to $3.91, recovering from a 10.47% decline earlier in the day. The company adjourned a special meeting to allow more time for voting on a proposed combination with Hyperliquid Strategies Inc. and Rorschach I LLC, with over 95% of shares voting in favor [7] - **Entero Therapeutics, Inc. (ENTO)**: Gained 3.68% to $3.10 after a 5.28% rise to $2.99. The company announced a rebranding to GridAI Technologies Corp., effective December 1, 2025, following its acquisition of GRID AI Corp. The new ticker symbol "GRDX" will debut on the Nasdaq Capital Market [8]

Core Insights - BioAtla, Inc. presented clinical data showing that Mecbotamab Vedotin (Mec-V) achieved a median overall survival (OS) of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, compared to approximately 12 months with approved agents [1][4][7] - The safety profile of Mec-V, both as a monotherapy and in combination with anti-PD-1 antibody, was manageable and consistent with its mechanism of selectively targeting the tumor microenvironment [1][2][4] Clinical Trial Details - In a Phase 2 clinical trial, 79 patients with advanced soft tissue sarcomas were treated with Mec-V, either as monotherapy (n=54) or in combination with anti-PD-1 antibody (n=25) [3] - A focused efficacy analysis was conducted on a subset of 44 patients who had treatment-refractory leiomyosarcoma, liposarcoma, or undifferentiated pleomorphic sarcoma [3] Efficacy and Safety Data - The median OS was 21.5 months across all patients, with 22.9 months in the combination arm and 18.4 months in the monotherapy arm [7] - The 12-month OS rate was 73%, significantly higher than the approximately 50% historically reported for approved agents in similar populations [7] - The disease control rate (DCR) was 52% across all patients, with two patients achieving partial responses [7] - Adverse events were generally low-grade and manageable, with no treatment-related deaths reported [7] Presentation Information - The data was presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlighting the potential of Mec-V to extend survival in patients with limited treatment options [1][6]

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company will present a Phase 2 trial of ozuriftamab vedotin (BA3021) at the 2025 ASCO Annual Meeting [1][2] Company Overview - BioAtla operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [3] - The company utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing [3] - BioAtla holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Clinical Development - BioAtla's first dual CAB bispecific T-cell engager antibody, BA3182, is in Phase 1 development, targeting EpCAM on adenocarcinomas [3] - The company has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The Phase 2 CAB-CTLA-4 antibody, evalstotug, is designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors [3]

Financial Data and Key Metrics Changes - Research and development (R&D) expenses for Q4 2024 were $11.6 million, down from $22.7 million in Q4 2023, a decrease of $11.1 million due to lower clinical development expenses [30] - General and administrative expenses were $4.6 million for Q4 2024, compared to $5.9 million in Q4 2023, a decrease of $1.3 million primarily due to lower stock-based compensation and personnel-related costs [31] - Net loss for Q4 2024 was $14.9 million, compared to a net loss of $26.9 million in Q4 2023 [31] - Cash and cash equivalents as of December 31, 2024, were $49 million, down from $111.5 million as of December 31, 2023 [32] Business Line Data and Key Metrics Changes - The CAB platform clinical programs are advancing, with promising results from the EpCAM and CAB CD3 bispecific T-cell engager antibody, showing tumor reduction in patients [9][12] - Mecbotamab Vedotin (Mec-V) demonstrated ongoing antitumor activity with multiple confirmed responses among 21 evaluable patients, with a median overall survival not yet reached at 35 months [15] - Ozuriftamab Vedotin (Oz-V) is showing a compelling clinical profile in treatment-refractory head and neck cancer patients, with a 100% disease control rate in HPV-positive patients [20][21] Market Data and Key Metrics Changes - The company is targeting a worldwide commercial opportunity of over $1 billion in peak sales for the second-line plus head and neck cancer population [22] - The overall survival rates for patients with MKRAS non-small cell lung cancer treated with Mec-V were reported at 66% and 58% at one and two years, respectively, exceeding standard care outcomes [15] Company Strategy and Development Direction - The company is focusing on advancing its internal priority programs while streamlining resources, including a workforce reduction of over 30% [28] - Discussions with potential collaborators for Phase 2 assets are ongoing, with a focus on the promising results from the CAB program [33] - The company is open to partnering discussions for various programs, including ROR2 and CTLA-4, to maximize shareholder value [78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical outcomes from the CAB program, highlighting its potential to transform treatment options for patients [33] - The company anticipates that the compelling results from its clinical trials will serve as important catalysts for future growth and partnerships [34] Other Important Information - The company has received fast track designation and actionable guidance from the FDA for the Oz-V monotherapy trial design [18] - The safety profile of Evalstotug, a CAB-CTLA-4 antibody, is differentiated with a low incidence of immune-mediated adverse events compared to traditional therapies [25] Q&A Session Summary Question: Update on partnered programs and discussions - Management indicated that discussions are ongoing for the ROR2 and CTLA-4 programs, with new interest expected due to recent data [36][38] Question: Data expectations for BA3182 - The company expects to report on the 300 microgram cohort data in the coming months, with potential for higher doses depending on patient recruitment [44][49] Question: HPV positive patients in head and neck cancer - Management noted that they do not have smoking correlation data for HPV positive patients but will obtain it post-call [63][66] Question: Future patient data for AXL program - The company plans to add more patients to the AXL program and is currently prioritizing the EpCAM program due to its broad applicability [75][76] Question: Strategic partnerships beyond ROR2 and CTLA-4 - Management is open to partnerships for other promising programs and is actively exploring various strategies to maximize shareholder value [78]